top of page

- Jul 24, 2012

NT-501 granted orphan-drug designation for macular telangiectasia type 2 (MacTel)

Recent Posts

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief

Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel

Neurotech Chief Medical Officer authors article in The Ophthalmologist

bottom of page